medigraphic.com
ISSN 0210-5187 (Electronic)

2019, Number 1

<< Back Next >>

Med Cutan Iber Lat Am 2019; 47 (1)

PPAR: Receptors and agonists. The future of therapy in dermatology?

Montilla CLE, Ball PE, Sáenz AM

Language: Spanish
References: 30
Page: 16-23
PDF size: 316.95 Kb.


ABSTRACT

Peroxisome proliferator-activated receptors (PPAR) are transcription factors activated by ligands that belong to the superfamily of nuclear hormone receptors. There are three distinct subtypes, PPARα, PPARβ/δ, PPARγ. It has been shown that all subtypes participate in the regulation of several genes involved in the metabolism of glucose, lipids and more recently in cutaneous homeostasis. Objectives: This document has been developed to provide an update on the biological functions of PPARs and how they influence the pathogenesis of various dermatological pathologies. Methodology: Literature review was carried out. Results: The expression of PPARs in the skin is an indisputable fact, the three subtypes are expressed in physiological conditions, in epidermis, dermis, sebaceous gland, hair follicle, as well as in human melanocytes and immature human Langerhans cells. Its activation produces variable effects on the skin, including the prodifferential, antiproliferative and immunomodulatory functions. Conclusion: The PPARs are object of multiple investigations related to cutaneous pathology, presenting as interesting therapeutic targets in diseases such as acne, rosacea, psoriasis, atopic dermatitis, scarring alopecias, neoplasias (melanoma, squamous cell carcinoma, vascular tumors) and other diverse disorders.


REFERENCES

  1. Schmuth M, Moosbrugger-Martinz V, Blunder S, Dubrac S. Role of PPAR, LXR, and PXR in epidermal homeostasis and inflammation. Biochim Biophys Acta. 2014; 1841 (3): 463-473.

  2. La Paglia L, Listí A, Caruso S, Amodeo V, Passiglia F, Bazan V et al. Potential role of ANGPTL4 in the cross talk between metabolism and cancer through PPAR signaling pathway. Hindawi Publishing Corporation. 2017; 8187235: 1-15.

  3. Gupta M, Mahajan VK, Metha KS, Chauhan PS, Rawat R. Peroxisome proliferator- activated receptors (PPARs) and PPAR agonists: the ‘future’ in dermatology therapeutics? Arch Dermatol Res. 2015; 307 (9): 767-780.

  4. Furue M, Takemura M, Nishio K, Sato Y, Nagata S, Kan N. Immunohistological localization of peroxisome proliferator-activated receptor α and γ in human sebaceous glands. Fukuoka Igaku Zasshi. 2016; 107 (11): 199-203.

  5. Schuetz R, Rawlings AV, Trevisan S, Imfeld D. The PPARα ligand, 10-hydroxyoctadecanoic acid, reduces facial pore size and pigmentation in normal skin. J Invest Dermatol. 2017; 137 (5): 1-10.

  6. Jung Y, Kim JC, Park NJ, Bong SK, Lee S, Jegal H. Eupatilin, an activator of PPARα, inhibits the development of oxazolone-induced atopic dermatitis symptoms in Balb/c mice. Biochem Biophys Res Commun. 2018; 496 (2): 508-514.

  7. Man MQ, Choi EH, Schmuth M, Crumrine D, Uchida Y, Elías PM. Basis for improved permeability barrier homeostasis induced by PPAR and LXR activators: liposensors stimulate lipid synthesis, lamellar body secretion, and post-secretory lipid processing. J Invest Dermatol. 2006; 126 (2): 386-392.

  8. Yessoufou A, Whali W. Multifaceted roles of peroxisome proliferator-activated receptors (PPARs) at the cellular and whole organism levels. Swiss Med Wkly. 2010; 140: w13071.

  9. Kuenzli S, Saurat JH. Peroxisome proliferator-actived receptors in cutaneous biology. Br J Dermatol. 2003; 149 (1): 229-236.

  10. Dozsa A, Dezs B, Toth B, Bacsi A, Poliska S, Camera E. PPARy mediated and arachidonic acid–dependent signaling is involved in differentiation and lipid production of human sebocytes. J Invest Dermatol. 2014; 134 (4): 910-920.

  11. Kang HY, Chung E, Lee M, Cho Y, Kang WH. Expression and function of peroxisome proliferator-activated receptors in human melanocytes. Br J Dermatol. 2004; 150 (3): 462-468.

  12. Damodaran A, Bangalore I, Shariff R, Joshi M, Cheng-Lian G. 12-Hydroxystearic acid: a peroxisome proliferator-activated receptor ligand that has antimelanogenic and antiinflammatory activity. J Am Acad Dermatol. 2016; 5 (74): 230-231.

  13. Ellis CN, Varani J, Fisher GJ, Zeigler M, Pershadsingh H, Benson S. Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. Arch Dermatol. 2000; 136 (5): 609-616.

  14. Kuenzli S, Saurat JH. Effect of topical PPAR beta/delta and PPAR gamma agonists on plaque psoriasis. A pilot study. Dermatology. 2003; 206 (3): 252-256.

  15. Shafiq N, Malhotra S, Pandhi P, Gupta M, Kumar B, Sandhu K. Pilot trial pioglitazone versus placebo in patients with plaque psoriasis. Int J Dermatol. 2005; 44 (4): 328-333.

  16. Chiba T, Takeuchi S, Esaki H. Topical application of PPARα (but not β/δ or γ) suppresses atopic dermatitis in NC/Nga mice. Allergy. 2012; 67 (7): 936-942.

  17. Sertznig P, Reichrath J. Peroxisome proliferator-activated receptors (PPARs) in dermatology. Dermatoendocrinol. 2011; 3 (3): 130-135.

  18. Dozsa A, Mihaly J, Dezso B, Csizmadia E, Keresztessy T, Marko L et al. Decreased peroxisome proliferator-activated receptor γ level and signalling in sebaceous glands of patients with acne vulgaris. Clin Exp Dermatol. 2016; 41 (5): 547-551.

  19. Zouboulis CC. Zileuton, a new efficient and safe systemic anti-acne drug. Dermatoendocrinol. 2009; 1: 188-192.

  20. Mastrofrancesco A, Ottaviani M, Aspite N, Cardinali G, Izzo E, Graupe K et al. Azelaic acid modulates the inflammatory response in normal human keratinocytes through PPARgamma activation. Exp Dermatol. 2010; 19 (9): 813-820.

  21. Silva-Abreu M, Espinoza LC, Rodríguez-Lagunas MJ, Fábrega MJ, Espina M, García ML et al. Human skin permeation studies with PPARγ agonist to improve its permeability and efficacy in inflammatory processes. Int J Mol Sci. 2017; 18 (12): 1-18.

  22. Harries MJ, Paus R. Scarring alopecia and the PPAR-gamma connection. J Invest Dermatol. 2009; 129 (5): 1066-1070.

  23. Islam N, Garza LA. Adipose and hair function: an aPPARent connection. J Invest Dermatol. 2018; 138 (3): 480-482.

  24. Baibergenova A, Walsh S. Use of pioglitazone in patients with lichen planopilaris. J Cutan Med Surg. 2012; 16 (2): 97-100.

  25. Mesinkovska NA, Tellez A, Dawes D, Piliang M, Bergfeld W. The use of oral pioglitazone in the treatment of lichen planopilaris. J Am Acad Dermatol. 2015; 72 (2): 355-356.

  26. Gaspar NK. DHEA and frontal fibrosing alopecia: molecular and physiopathological mechanisms. An Bras Dermatol. 2016; 91 (6): 776-780.

  27. Degueurce G, D’Errico I, Pich C, Ibberson M, Schütz F, Montagner A et al. Identification of a novel PPARβ/δ/miR-21-3p axis in UV-induced skin inflammation. EMBO Molecular Medicine. 2016; 8 (8): 919-936.

  28. Borland MG, Kehres EM, Lee C, Wagner AL, Shannon BE, Albrecht PP et al. Inhibition of tumorigenesis by peroxisome proliferator-activated receptor (PPAR)-dependent cell cycle blocks in human skin carcinoma cells. Toxicology. 2018; 404-405: 25-32.

  29. Behera R, Kaur A, Webster MR, Kim S, Ndoye A, Kugel CH et al. Inhibition of age-related therapy resistance in melanoma by rosiglitazone-mediated induction of klotho. Clin Cancer Res. 2017; 23 (12): 3181-3191.

  30. Borland MG, Yao PL, Kehres EM, Lee C, Pritzlaff AM, Ola E et al. Editor’s highlight: PPARβ/δ and PPARγ inhibit melanoma tumorigenicity by modulating inflammation and apoptosis. Toxicol Sci. 2017; 159 (2): 436-448.




2020     |     www.medigraphic.com